Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis

ABSTRACT Introduction: Amyotrophic lateral sclerosis (ALS) is a debilitating neurologic disorder with poor survival rates and no clear biomarkers for disease diagnosis and prognosis. Methods: We compared serum microRNA (miRNA) expression from patients with ALS with healthy controls and patients with...

Full description

Saved in:
Bibliographic Details
Published in:Muscle & nerve Vol. 58; no. 2; pp. 261 - 269
Main Authors: Raheja, Radhika, Regev, Keren, Healy, Brian C., Mazzola, Maria Antonietta, Beynon, Vanessa, Von Glehn, Felipe, Paul, Anu, Diaz‐Cruz, Camilo, Gholipour, Taha, Glanz, Bonnie I., Kivisakk, Pia, Chitnis, Tanuja, Weiner, Howard L., Berry, James D., Gandhi, Roopali
Format: Journal Article
Language:English
Published: United States Wiley Subscription Services, Inc 01.08.2018
Subjects:
Adult
ALS
Alzheimer Disease - blood
Alzheimer Disease - physiopathology
Alzheimer's disease
Amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis - blood
Amyotrophic Lateral Sclerosis - physiopathology
Biomarkers
Biomarkers - blood
Cohort Studies
Cross-Sectional Studies
Diagnosis
disease comparisons
Disease control
Disease Progression
Female
Gene Expression Regulation
Humans
longitudinal analysis
Longitudinal Studies
Male
Medical prognosis
microRNA
MicroRNAs - blood
Middle Aged
miRNA
Multiple sclerosis
Multiple Sclerosis - blood
Multiple Sclerosis - physiopathology
Muscles
Neurodegenerative diseases
Parameter identification
Patients
Ribonucleic acid
RNA
serum
ALS
longitudinal analysis
microRNA
disease comparisons
serum
biomarkers
ISSN:0148-639X, 1097-4598, 1097-4598
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Introduction: Amyotrophic lateral sclerosis (ALS) is a debilitating neurologic disorder with poor survival rates and no clear biomarkers for disease diagnosis and prognosis. Methods: We compared serum microRNA (miRNA) expression from patients with ALS with healthy controls and patients with multiple sclerosis and Alzheimer disease. We also correlated miRNA expression in cross‐sectional and longitudinal cohorts of ALS patients with clinical parameters. Results: We identified 7 miRNAs (miR‐192‐5p, miR‐192‐3p, miR‐1, miR‐133a‐3p, miR‐133b, miR‐144‐5p, miR‐19a‐3p) that were upregulated and 6 miRNAs (miR‐320c, miR‐320a, let‐7d‐3p, miR‐425‐5p, miR‐320b, miR‐139‐5p) that were downregulated in patients with ALS compared with healthy controls, patients with Alzheimer disease, and patients with multiple sclerosis. Changes in 4 miRNAs (miR‐136‐3p, miR‐30b‐5p, miR‐331‐3p, miR‐496) correlated positively and change in 1 miRNA (miR‐2110) correlated negatively with changes in clinical parameters in longitudinal analysis. Discussion: Our findings identified serum miRNAs that can serve as biomarkers for ALS diagnosis and progression. Muscle Nerve 58: 261–269, 2018
Bibliography:National Center for Advancing Translational Sciences
B. C. Healy has served on the scientific advisory board for Biogen and Worldwide Medical Biostatistics and has received research support from Merck Serono, Genzyme, Novartis, and Google Life Sciences. C. Diaz‐Cruz has received research support from Merck Serono and Google Life Sciences. T. Gholipour has received research support from Merck Serono, compensation as a reviewer from Boehringer Ingelheim, and spouse received compensation from Boehringer Ingelheim as a reviewer. B. I. Glanz has received research support from Merck Serono SA. P. Kivisakk has received research support from EMD Serono, Sanofi Genzyme, Verily Life Sciences. T. Chitnis served on clinical trial advisory boards for Novartis Pharmaceuticals and Genzyme‐Sanofi; consulted for Biogen Idec, Novartis, Genzyme‐Sanofi, Genentech Roche; and has received research support from EMD Serono, Novartis, Biogen, and Verily. H. L. Weiner has served on the scientific advisory board for Teva Pharmaceutical Industries, Biogen Idec, Novartis, Sanofi‐Aventis and has consulted for Therapix, Biogen, Novartis, Serono, Teva, and Sanofi. J. D Berry has consulted with Biogen, Denali Therapeutics and Neuraltus Pharmaceuticals and has received research support from Voyager Therapeutics and GSK, Cytokinetics, Brainstorm Cell Therapeutics, and Novartis. R. Gandhi has received research support from Novartis, Biogen, EMD Serono, and Sanofi. R. Raheja, K. Regev, M. A Mazzola, V. Beynon, F. Glehn, and A. Paul have no conflicts to report.
Conflicts of Interest
R. R. and K. R. contributed equally to this work.
Funding
This study was funded by National Institutes of Health funds via the
(UH2/UH3 Grant TR000890).
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
These authors contributed equally to this work.
ISSN:0148-639X
1097-4598
1097-4598
DOI:10.1002/mus.26106